Expertise in
2
conditions

Dr. Rebecca L. Moroose

Internal Medicine
Florida Home Health Equipment And Supplies Inc
22 Underwood St Fl 3, 
Orlando, FL 
Expertise in
2
conditions
Florida Home Health Equipment And Supplies Inc
22 Underwood St Fl 3, 
Orlando, FL 

Overview

Rebecca Moroose is a primary care provider, practicing in Internal Medicine in Orlando, Florida.

Dr. Moroose is highly rated in 2 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Breast Cancer in Men, Li-Fraumeni Syndrome, and BRCA Positive Breast Cancer.

She is actively involved in clinical research, co-authoring 14 peer reviewed articles and participating in 7 clinical trials.

Specialties

Internal Medicine

Licenses

Internal Medicine in FL

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO

Locations

Florida Home Health Equipment and Supplies Inc
22 Underwood St Fl 3, Orlando, FL 32806

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05)
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05)
Enrollment Status: Active_not_recruiting
Publish Date: July 22, 2026
Intervention Type: Drug
Study Drugs: Tucatinib, Trastuzumab, Pertuzumab
Study Phase: Phase 3
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Enrollment Status: Completed
Publish Date: August 14, 2023
Intervention Type: Drug
Study Drugs: tucatinib, capecitabine, trastuzumab
Study Phase: Phase 2
An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan Versus Treatment of Physician Choice in Patients With Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments
An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan Versus Treatment of Physician Choice in Patients With Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments
Enrollment Status: Completed
Publish Date: June 15, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancer
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancer
Enrollment Status: Completed
Publish Date: August 12, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase I/II, Single Arm, Open-label Study of Ribociclib in Combination With Everolimus + Exemestane in the Treatment of Men and Postmenopausal Women With HR+, HER2- Locally Advanced or Metastatic Breast Cancer Following Progression on a CDK 4/6 Inhibitor
A Phase I/II, Single Arm, Open-label Study of Ribociclib in Combination With Everolimus + Exemestane in the Treatment of Men and Postmenopausal Women With HR+, HER2- Locally Advanced or Metastatic Breast Cancer Following Progression on a CDK 4/6 Inhibitor
Enrollment Status: Completed
Publish Date: May 05, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
An Open-Label, Multi-Center Expanded Access Program of Abemaciclib for the Treatment of Hormone Receptor Positive, HER2 Negative Advanced or Metastatic Breast Cancer in Patients With Disease Progression on Prior Therapies
An Open-Label, Multi-Center Expanded Access Program of Abemaciclib for the Treatment of Hormone Receptor Positive, HER2 Negative Advanced or Metastatic Breast Cancer in Patients With Disease Progression on Prior Therapies
Enrollment Status: Approved_for_marketing
Publish Date: October 31, 2017
Intervention Type: Drug
View 6 Less Clinical Trials

14 Total Publications

Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial.
Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial.
Journal: JAMA oncology
Published: September 25, 2025
Similar Doctors
Expertise in
9
conditions
Dr. Richard E. Pratley
Internal Medicine
Expertise in
9
conditions
Dr. Richard E. Pratley
Internal Medicine

AdventHealth Medical Group Diabetes And Endocrinology At Orlando

2415 N Orange Ave, Suite 502, 
Orlando, FL 
 (4.3 miles away)
407-303-2801
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Richard Pratley is a primary care provider, practicing in Internal Medicine in Orlando, Florida. Dr. Pratley is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Type 2 Diabetes (T2D), Low Blood Sugar, Type 1 Diabetes (T1D), and Maturity Onset Diabetes of the Young. Dr. Pratley is currently accepting new patients.

Expertise in
36
conditions
Dr. Dinesh Khanna
Internal Medicine
Expertise in
36
conditions
Dr. Dinesh Khanna
Internal Medicine
Before you request

Premier Medical Associates

1580 Santa Barbara Blvd Ste C, 
The Villages, FL 
 (43.7 miles away)
352-259-2159
Languages Spoken:
English, Hindi, Urdu
See accepted insurances
Accepting New Patients

Dinesh Khanna is a primary care provider, practicing in Internal Medicine in The Villages, Florida. Dr. Khanna is highly rated in 36 conditions, according to our data. His clinical expertise encompasses Systemic Sclerosis (SSc), Scleroderma, Interstitial Lung Disease, Acute Interstitial Pneumonia, and Lung Transplant. Dr. Khanna is board certified in American Board Of Internal Medicine. Dr. Khanna is currently accepting new patients.

Expertise in
15
conditions
Dr. Adriana Otto
Internal Medicine
Expertise in
15
conditions
Dr. Adriana Otto
Internal Medicine

Orange Primary Care P.A.

1400 S Orlando Ave Ste 205, 
Winter Park, FL 
 (6.1 miles away)
321-972-8274
Languages Spoken:
English
See accepted insurances

Adriana Otto is a primary care provider, practicing in Internal Medicine in Winter Park, Florida. Dr. Otto is highly rated in 15 conditions, according to our data. Her clinical expertise encompasses Mitral Stenosis, Heart Tumor, Atrial Myxoma, Heart Valve Repair, and Aortic Valve Replacement.

Frequently Asked Questions about Dr. Rebecca L. Moroose

How do I make an appointment with Dr. Rebecca L. Moroose?

You can book an appointment with Dr. Rebecca L. Moroose by calling their office at 407-648-3800. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Rebecca L. Moroose a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Rebecca L. Moroose is classified as an Distinguished expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Rebecca L. Moroose specialize in?

While Dr. Rebecca L. Moroose is a Internal Medicine, they have specific expertise in Breast Cancer, Breast Cancer in Men, and Li-Fraumeni Syndrome. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Rebecca L. Moroose participate in research or clinical trials?

Yes. Dr. Rebecca L. Moroose has published 14 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Rebecca L. Moroose's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Rebecca L. Moroose accept my insurance?

Dr. Rebecca L. Moroose accepts most major insurance plans, including Cigna. We recommend calling the office directly at 407-648-3800 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Moroose's expertise for a condition
ConditionClose
    View All 7 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile